NO20001343D0 - Fremgangsmåter og sammensetninger for behandling av pulmonære forstyrrelser ved anvendelse av optisk ren (S)-salmeterol - Google Patents

Fremgangsmåter og sammensetninger for behandling av pulmonære forstyrrelser ved anvendelse av optisk ren (S)-salmeterol

Info

Publication number: NO20001343D0
Authority: NO; Norway
Prior art keywords: salmeterol; compositions; treatment; methods; optically pure
Prior art date: 1997-09-16

Application number

NO20001343A

Other languages

English (en)

Norwegian (no)

Other versions

NO20001343L (no

Inventor

Thomas P Jerussi

Original Assignee

Sepracor Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1997-09-16

Filing date

2000-03-15

Publication date

2000-03-15

2000-03-15 Application filed by Sepracor Inc filed Critical Sepracor Inc

2000-03-15 Publication of NO20001343L publication Critical patent/NO20001343L/no

2000-03-15 Publication of NO20001343D0 publication Critical patent/NO20001343D0/no

Links

239000000203 mixture Substances 0.000 title abstract 2
GIIZNNXWQWCKIB-RUZDIDTESA-N (S)-salmeterol Chemical compound C1=C(O)C(CO)=CC([C@H](O)CNCCCCCCOCCCCC=2C=CC=CC=2)=C1 GIIZNNXWQWCKIB-RUZDIDTESA-N 0.000 title 1
208000019693 Lung disease Diseases 0.000 title 1
GIIZNNXWQWCKIB-UHFFFAOYSA-N Serevent Chemical compound C1=C(O)C(CO)=CC(C(O)CNCCCCCCOCCCCC=2C=CC=CC=2)=C1 GIIZNNXWQWCKIB-UHFFFAOYSA-N 0.000 abstract 1
230000002411 adverse Effects 0.000 abstract 1
102000016966 beta-2 Adrenergic Receptors Human genes 0.000 abstract 1
108010014499 beta-2 Adrenergic Receptors Proteins 0.000 abstract 1
229940124630 bronchodilator Drugs 0.000 abstract 1
230000000694 effects Effects 0.000 abstract 1
230000003389 potentiating effect Effects 0.000 abstract 1
229960004017 salmeterol Drugs 0.000 abstract 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
- A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
- A61K9/008—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy comprising drug dissolved or suspended in liquid propellant for inhalation via a pressurized metered dose inhaler [MDI]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/08—Bronchodilators

Landscapes

Health & Medical Sciences (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Veterinary Medicine (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Chemical & Material Sciences (AREA)
Public Health (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
Pulmonology (AREA)
Epidemiology (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Organic Chemistry (AREA)
General Chemical & Material Sciences (AREA)
Otolaryngology (AREA)
Chemical Kinetics & Catalysis (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Medicinal Preparation (AREA)
Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

NO20001343A 1997-09-16 2000-03-15 Fremgangsmåter og sammensetninger for behandling av pulmonære forstyrrelser ved anvendelse av optisk ren (S)-salmeterol NO20001343D0 (no)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US08/931,636 US6254882B1 (en)	1997-09-16	1997-09-16	Methods and compositions for treating pulmonary disorders using optically pure (S)—salmeterol
PCT/US1998/018845 WO1999013867A1 (fr)	1997-09-16	1998-09-10	Compositions de traitement de troubles pulmonaires a base de (s)-salmeterol optiquement pur et methodes correspondantes

Publications (2)

Publication Number	Publication Date
NO20001343L NO20001343L (no)	2000-03-15
NO20001343D0 true NO20001343D0 (no)	2000-03-15

Family

ID=25461118

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
NO20001343A NO20001343D0 (no)	1997-09-16	2000-03-15	Fremgangsmåter og sammensetninger for behandling av pulmonære forstyrrelser ved anvendelse av optisk ren (S)-salmeterol

Country Status (19)

Country	Link
US (1)	US6254882B1 (fr)
EP (1)	EP1007008B1 (fr)
JP (1)	JP2001516715A (fr)
KR (1)	KR20010030610A (fr)
CN (1)	CN1270515A (fr)
AT (1)	ATE268166T1 (fr)
AU (1)	AU754275B2 (fr)
BG (1)	BG104240A (fr)
BR (1)	BR9812643A (fr)
CA (1)	CA2304265A1 (fr)
CZ (1)	CZ290394B6 (fr)
DE (1)	DE69824296T2 (fr)
ES (1)	ES2221991T3 (fr)
HU (1)	HUP0003488A3 (fr)
IL (1)	IL135022A0 (fr)
NO (1)	NO20001343D0 (fr)
NZ (1)	NZ503563A (fr)
SK (1)	SK3722000A3 (fr)
WO (1)	WO1999013867A1 (fr)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DE19921693A1 (de) *	1999-05-12	2000-11-16	Boehringer Ingelheim Pharma	Neuartige Arzneimittelkompositionen auf der Basis von anticholinergisch wirksamen Verbindungen und ß-Mimetika
EP1212089B1 (fr) *	1999-08-21	2006-03-22	ALTANA Pharma AG	Combinaison synergetique de roflumilast et salmeterol
GB9924992D0 (en) *	1999-10-21	1999-12-22	Glaxo Group Ltd	Pharmaceutical aerosol formulations
DE60017450T2 (de) *	1999-11-23	2006-03-02	Glaxo Group Ltd., Greenford	Pharmazeutische formulierungen enthaltend salmeterol
WO2003024396A2 (fr)	2001-09-17	2003-03-27	Glaxo Group Limited	Formulations de medicament en poudre seche
DE60302454T2 (de) *	2002-04-19	2006-08-17	Yissum Research Development Company Of The Hebrew University Of Jerusalem	Beta-agonisten-verbindungen mit stickoxid-donatoren-gruppen und reaktionsfähige sauerstoffspezies-fängergruppen und ihre verwendung bei der behandlung von atemwegsstörungen
US20060247216A1 (en) *	2002-10-25	2006-11-02	Haj-Yehia Abdullah I	Steroid compounds comprising superoxide dismutase mimic groups and nitric oxide donor groups, and their use in the preparation of medicaments
AU2004240629B2 (en) *	2003-05-16	2010-02-25	Arriva Pharmaceuticals, Inc.	Treatment of respiratory disease by inhalation of synthetic matrix metalloprotease inhibitors
JPWO2004112791A1 (ja) *	2003-06-23	2006-07-27	協和醗酵工業株式会社	肺疾患の治療および／または予防剤
US8426475B2 (en)	2005-04-13	2013-04-23	Astion Development A/S	Treatment of connective tissue diseases of the skin
US8415390B2 (en)	2008-05-30	2013-04-09	Microdose Therapeutx, Inc.	Methods and compositions for administration of oxybutynin
US9119777B2 (en)	2008-05-30	2015-09-01	Microdose Therapeutx, Inc.	Methods and compositions for administration of oxybutynin

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
ZW6584A1 (en)	1983-04-18	1985-04-17	Glaxo Group Ltd	Phenethanolamine derivatives
NZ235605A (en)	1989-10-10	1992-12-23	Glaxo Group Ltd	(r)-(-)-4-hydroxy-alpha 1 -(((6-(4-phenylbutoxy)hexyl)amino)methyl)-1,3-benzenedimethanol and pharmaceutical compositions
GB9024366D0 (en)	1990-11-09	1991-01-02	Glaxo Group Ltd	Medicaments
GB9026005D0 (en)	1990-11-29	1991-01-16	Glaxo Group Ltd	Drug material suitable for micronisation
GB9107196D0 (en) *	1991-04-05	1991-05-22	Sandoz Ag	Improvements in or relating to organic compounds
CA2286913C (fr) *	1997-04-30	2008-12-09	Bridge Pharma, Inc.	Composition et procedes employant un eutomere

1997
- 1997-09-16 US US08/931,636 patent/US6254882B1/en not_active Expired - Fee Related
1998
- 1998-09-10 WO PCT/US1998/018845 patent/WO1999013867A1/fr not_active Ceased
- 1998-09-10 IL IL13502298A patent/IL135022A0/xx unknown
- 1998-09-10 JP JP2000511490A patent/JP2001516715A/ja not_active Withdrawn
- 1998-09-10 ES ES98944834T patent/ES2221991T3/es not_active Expired - Lifetime
- 1998-09-10 HU HU0003488A patent/HUP0003488A3/hu unknown
- 1998-09-10 SK SK372-2000A patent/SK3722000A3/sk unknown
- 1998-09-10 KR KR1020007002801A patent/KR20010030610A/ko not_active Abandoned
- 1998-09-10 AT AT98944834T patent/ATE268166T1/de not_active IP Right Cessation
- 1998-09-10 CA CA002304265A patent/CA2304265A1/fr not_active Abandoned
- 1998-09-10 DE DE69824296T patent/DE69824296T2/de not_active Expired - Fee Related
- 1998-09-10 AU AU92283/98A patent/AU754275B2/en not_active Ceased
- 1998-09-10 CZ CZ2000916A patent/CZ290394B6/cs not_active IP Right Cessation
- 1998-09-10 EP EP98944834A patent/EP1007008B1/fr not_active Expired - Lifetime
- 1998-09-10 NZ NZ503563A patent/NZ503563A/en unknown
- 1998-09-10 CN CN98809163A patent/CN1270515A/zh active Pending
- 1998-09-10 BR BR9812643-1A patent/BR9812643A/pt not_active IP Right Cessation
2000
- 2000-03-14 BG BG104240A patent/BG104240A/xx unknown
- 2000-03-15 NO NO20001343A patent/NO20001343D0/no unknown

Also Published As

Publication number	Publication date
NO20001343L (no)	2000-03-15
HUP0003488A3 (en)	2003-05-28
IL135022A0 (en)	2001-05-20
CZ2000916A3 (cs)	2000-08-16
EP1007008A1 (fr)	2000-06-14
CN1270515A (zh)	2000-10-18
HUP0003488A2 (hu)	2001-02-28
ES2221991T3 (es)	2005-01-16
EP1007008A4 (fr)	2002-06-12
ATE268166T1 (de)	2004-06-15
SK3722000A3 (en)	2000-07-11
BG104240A (en)	2001-04-30
US6254882B1 (en)	2001-07-03
JP2001516715A (ja)	2001-10-02
NZ503563A (en)	2002-07-26
DE69824296T2 (de)	2005-06-30
WO1999013867A1 (fr)	1999-03-25
CZ290394B6 (cs)	2002-07-17
DE69824296D1 (de)	2004-07-08
CA2304265A1 (fr)	1999-03-25
AU9228398A (en)	1999-04-05
EP1007008B1 (fr)	2004-06-02
KR20010030610A (ko)	2001-04-16
BR9812643A (pt)	2000-08-22
AU754275B2 (en)	2002-11-07

Similar Documents

Publication	Publication Date	Title
NO20001343L (no)	2000-03-15	FremgangsmÕter og sammensetninger for behandling av pulmonære forstyrrelser ved anvendelse av optisk ren (S)-salmeterol
DK11593D0 (da)	1993-02-01	Fremgangsmaade til fremstilling af (s)-citalopram og forbindelser der kan anvendes som mellemprodukt ved fremgangsmaaden
DK144694A (da)	1995-06-29	Fremgangsmåde til fremstilling af en optisk ren enantiomer af formoterol
DE69118359D1 (de)	1996-05-02	Optisch reines r(-)albuterol zur behandlung von asthma
NO944644D0 (no)	1994-12-02	Fremstilling av 3,4,4-trisubstituert-piperidinyl-N-alkylkarboksylater og mellomprodukter
ATE240139T1 (de)	2003-05-15	Co-kristallisationsprozess
IN184142B (fr)	2000-06-17
NO983636L (no)	1998-10-19	FremgangsmÕte for behandling av brekninger og sykdomstilstander i sentralnervesystemet ved anvendelse av optisk rent (+) norcisaprid
DK0787715T3 (da)	2000-04-25	Fremgangsmåde til racematspaltning af tramadol
BR0007643A (pt)	2001-10-16	Processo para obter ésteres de (nitroximetil) fenila de derivados de aspirina, e, (hidroximetil) feniléter de derivados de aspirina
ES8601100A1 (es)	1985-10-16	Un procedimiento para producir 3-(3, 4-dihidroxifenil) serina
DK0755919T3 (da)	2000-04-25	Substituerede kanelsyreguanidider, fremgangsmåde til deres fremstilling, deres anvendelse som hjerte-kredsløbs-medikament e
DK0938584T3 (da)	2008-09-22	Fremgangsmåde til fremstilling af (S)-eller (R)-3,3,3-trifluor-2-hydroxy-2-methylpropionsyre
DK0968997T3 (da)	2004-02-02	Fremgangsmåde til fremstilling af S-aryl-L-cystein og derivater
BR9103481A (pt)	1992-05-12	Composto,estereoisomero,composicao farmaceutica e processo para preparar um composto
FR2719998B1 (fr)	1996-09-27	Composition immunisante anti-hélicobacter pylori à base de catalase.
ATE339423T1 (de)	2006-10-15	Verfahren zur herstellung von 4'-o-substituierten 4'-demethyl-1 desoxypodophyllotoxinderivaten und geometrischen isomeren davon ,und antikrebspräparat, das diese enthält
DK0924206T3 (da)	2003-07-28	Fremgangsmåde til fremstilling af (R)-3-hydroxy-4-butyrolacton anvendeligt til fremstilling af (R)-carnitin
AU755526C (en)	2003-07-24	1-(4-arylpiperazin-1-YL)-3-(2-oxopyrrolidin/piperidin-1-YL) propanes used as potential therapeutic agents for hypertension, ischemia, cardiovascular and other adrenergic receptors related disorders, a process for preparing such compounds and a method of treating above diseases using the compounds
NO20030876L (no)	2003-02-25	Fremgangsmåte for racemisering av 1-benzyl-4-(4-fluorfenyl)-3- hydroksymetyl-1,2,3,6-tetrahydropyridin for bruk som mellomprodukt i syntese avparoxetin
BR0206532A (pt)	2004-03-23	Componente diamantóide superior selecionado enriquecido, composição, componentes de tetramantano, de pentamantano, de hexamantano, de heptamantano, de octamantano, de nonamantano, de decamantano, e de undecamantano enriquecidos, e, processos para a recuperação de uma composição enriquecida em componentes diamantóides superiores e, para a recuperação de um diamantóide superior enriquecido
DK0854859T3 (da)	2000-09-25	Fremgangsmåde til fremstilling af 4-cyano-2,5-difluoranilin
NO922871L (no)	1992-07-20	Fremgangsmaate for fremstilling av homokirale aminer og fremgangsmaate ved fremstilling av mellomprodukter for fremstilling derav, samt mellomproduktene fremstilt i henhold til den fremgangsmaaten